FDA to Convene Meeting on HIV Patient-Focused Drug Development and HIV Cure Research

Content From: Richard Klein, Patient Liaison Program Director, Office of Health and Constituent Affairs, Food and Drug AdministrationPublished: May 20, 20131 min read


FDAMeetingThe Food and Drug Administration (FDA) wants to talk to people living with HIV (PLWH) and HIV/AIDS advocates. On June 14, under its Patient-Focused Drug Development initiative, FDA will ask PLWH to join an open public discussion about:

  • the impact of HIV on your daily life,
  • experience with currently available therapies to treat HIV,
  • your views on issues related to HIV cure research, including perceived benefits and acceptable risk for participating in HIV cure research, and
  • how best to ensure clear communication of potential benefits and possible risks through informed consent.

This discussion is intended to help improve drug development and treatment, and get patients’ perspective into HIV cure research. The meeting takes place on June 14, 2013, from 9:30 AM – 5:30 PM at FDA’s White Oak Campus, located at:

10903 New Hampshire Avenue

Building 31, (in The Great Room)

Silver Spring, Maryland 20993

There is no cost to attend, but if you would like to attend, please register by June 5. Those who cannot attend will be able to view the meeting via webcast. However, the webcast will not be interactive, so viewers will not be able to actively participate in the discussion.

FDA has prepared a list of questions that we hope will frame and guide the discussion at this meeting. You can review those questions, read more about the meeting, and register at this link.